Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01842282 · ClinicalTrials.gov registry record · Phase 2
Amlexanox for Type 2 Diabetes and Obesity
A Phase 2 study, sponsored by University of Michigan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01842282 is a Phase 2 study that was terminated before completion, run by University of Michigan. The registered enrollment target is 7 participants.
The verdict
NCT01842282, a Phase 2 study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day. The investigators plan to continue therapy for a period of 12 weeks followed by a follow-up 4 weeks after therapy ends. The investigators will evaluate the changes in metabolic parameters (e.g. blood cholesterol, liver function, insulin resistance) and body composition characteristics (e.g. the pattern of fat distribution in the body). Seven eligible subjects in this study will also be evaluated for a change in liver disease by a liver biopsy.
Interventions
- DRUG Amlexanox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-07-19 |
| Est. Completion | 2014-02-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01842282
The ClinicalTrials.gov registry entry for NCT01842282 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amlexanox is the first listed.
NCT01842282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01842282 about?
NCT01842282 is a clinical study titled "Amlexanox for Type 2 Diabetes and Obesity". This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day. The investigators plan to continue therapy for a period of 12 weeks follo...
What is the current status of trial NCT01842282?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2013-07-19. Estimated completion is 2014-02-25.
What interventions are being tested in trial NCT01842282?
The interventions under investigation include: Amlexanox (DRUG).
Who is sponsoring clinical trial NCT01842282?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.